1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zhaoke Ophthalmology Ltd.

Zhaoke Ophthalmology Ltd.

HHKEX:6622
1.90
HKD
-0.04
(-2.06%)
1.62BMarket Cap
Mar 29Next Earn
Zhaoke Ophthalmology Ltd.
HKEX:6622
(Hong Kong Exchange)

Recent

price

1.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
CNY
- -
- -
- -
- -
0.03
0.13
0.06
- -
Revenue per Share
-0.23
-1.36
-5.16
-0.75
-0.71
-0.43
-0.38
- -
Basic EPS, GAAP
-0.15
-0.52
-0.82
-1.05
-0.77
-0.55
-0.48
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.05
-1.38
4.6
4.32
3.75
3.48
2.88
2.88
Book Value per Share
-0.12
-1.64
4.31
3.7
3.03
2.72
2.18
2.18
Tangible Book Value per Share
535
535
412
542
544
546
547
547
Basic Weighted Avg Shares
- -
- -
- -
- -
19
69
32
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
-2,409.11
-411.94
-861.56
- -
Operating Margin (%)
17
20
26
35
49
54
52
- -
Depreciation Expense
-122
-727
-2,130
-407
-385
-237
-209
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-2,053.54
-342.58
-653.6
- -
Profit Margin (%)
196
860
2,120
1,778
1,458
1,302
1,045
1,045
Working Capital
26
23
21
28
22
16
9
9
LT Debt
-26
-746
2,495
2,348
2,048
1,900
1,576
1,576
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-16.82
-17.51
-12.03
-12.02
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
223
258
283
LT Borrowings
- -
- -
- -
LT Finance Leases
16
13
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
546
546
548
Market Capitalization
616
1,296
1,457

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1,615
1,475
1,374
Cash, Cash Equivalents & STI
1,191
1,054
961
Accounts Receivable, Net
1
4
14
Inventories
15
14
15
Total Current Liabilities
313
335
328
Payables & Accruals
- -
- -
- -
ST Debt
223
258
283
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-95.5%
-17.06%
Free Cash Flow
- -
4.58%
-11%
Net Income, GAAP
- -
11.26%
-12%
Sales/Revenue/Turnover
- -
- -
-53.88%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
19
2024
- -
- -
69
2025
- -
- -
32

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.71
2024
- -
- -
-0.43
2025
- -
- -
-0.38

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zhaoke Ophthalmology Limited (SEHK: 6622) is a Cayman Islands-incorporated ophthalmic pharmaceutical company founded in 2017 and headquartered in Nansha, Guangzhou, People's Republic of China, that engages in the research, development, manufacturing, and commercialization of therapies addressing major eye diseases across the anterior and posterior segments, including dry eye disease (DED), myopia, presbyopia, wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and glaucoma. The company maintains a fully integrated platform with a state-of-the-art production facility in Nansha and offers a comprehensive pipeline of 13 innovative drugs and 12 generic drugs; flagship innovative assets include Cyclosporine A (CsA) Ophthalmic Gel and NVK-002 (Atropine Sulfate Eye Drops) for DED under NDA review with NMPA, TAB014 (Bevacizumab Intravitreal Injection) in Phase III for wAMD, BRIMOCHOL™ PF in preparation for Phase III for presbyopia, and ZKY001 for corneal epithelial defects, alongside generic offerings targeting broader patient access. Zhaoke Ophthalmology primarily serves the Chinese market with expansion into ASEAN, South Korea, Hong Kong, the GCC, Middle East, and Indonesia through strategic partnerships, including its second collaboration with PT Ferron in November 2025 for BRIMOCHOL™ PF commercialization in Indonesia, agreements with Jamjoom Pharmaceuticals in June 2025 for CsA Ophthalmic Gel in the Middle East, Lunatus in March 2025 for BRIMOCHOL™ PF in the GCC, Somerset Therapeutics and FAREVA in June-July 2025 for manufacturing and global supply, and Seefunge in early 2025 for joint product launches; these alliances support its global growth strategy while advancing near-term commercialization goals.